12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Company News  |  Deals

Exelixis, Merck deal

Exelixis granted Merck exclusive, worldwide rights to its preclinical phosphoinositide 3-kinase (PI3K) delta program, including lead inhibitor XL499 and related compounds. Exelixis will receive...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >